Securities code: 300558 securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022-010 Betta Pharmaceuticals Co.Ltd(300558)
Announcement on the appointment of senior managers by the company
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) convened the 28th meeting of the third board of directors on January 21, 2022, deliberated and adopted the proposal on appointing Mr. Cai Wanyu as the senior management of the company. According to the needs of the company’s operation and management, nominated by Chairman Ding Liming and approved by the nomination committee of the board of directors, the board of directors agreed to appoint vice president Cai Wanyu as the senior vice president of the company to be responsible for the management of the production center and Shengzhou industrial base. The term of office starts from the date of deliberation and approval by the board of directors to the date of expiration of the third board of directors. The independent directors of the company have expressed their independent opinions on the above-mentioned appointment matters. For details, see the company’s disclosure on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Relevant announcements on.
See the attachment for the resume of Mr. Cai Wanyu.
It is hereby announced.
Betta Pharmaceuticals Co.Ltd(300558) attachment of the board of directors on January 23, 2022:
resume
Mr. Cai Wanyu, born in February 1962, Chinese nationality, without overseas residency, Bachelor of China Pharmaceutical University, senior engineer and licensed pharmacist, is currently the senior vice president of the company, the general manager of the company’s wholly-owned subsidiary Betta Pharmaceuticals Co.Ltd(300558) (Shengzhou) Co., Ltd. and the supervisor of Qiyuan Biology (Hangzhou) Co., Ltd. With more than 30 years of rich experience, he has been responsible for the production and quality of large pharmaceutical enterprises, and has strong project planning, organization ability and excellent team building ability. He is a core member of the national first prize for scientific and technological progress “ektinib hydrochloride industrialization project” and a technical expert member of Zhejiang Provincial Science and technology expert database. He presided over or participated in two major national science and technology projects of “major new drug creation” led by the company and the national strong foundation project of industrial transformation and upgrading, and won the provincial excellent achievement award of scientific and technological development. In charge of the company’s production center.
Mr. Cai Wanyu left the company’s senior management on August 4, 2020, and has directly held 0.02% of the company’s shares due to equity incentive exercise since the date of departure; Indirectly hold the company’s shares by holding 1.11% of Zhejiang Beicheng investment management partnership (limited partnership). Mr. Cai Wanyu has no relationship with the controlling shareholder and actual controller of the company, shareholders holding more than 5% of the company and their actual controllers, other directors, supervisors and senior managers of the company, has not been punished by China Securities Regulatory Commission and other relevant departments and securities exchanges, and complies with laws, administrative regulations, departmental rules, normative documents Qualifications required by Shenzhen Stock Exchange GEM Listing Rules, other rules of Shenzhen Stock Exchange and Betta Pharmaceuticals Co.Ltd(300558) articles of association. After searching the directory of dishonest Executees on the website of the Supreme People’s court, Mr. Cai Wanyu is not dishonest Executees.
